Study By Former FDA Advisors Finds Agency Is Biased Towards Approving New Drugs
Critics point to the recent FDA approval of the controversial new Alzheimer's drug Aduhelm, which led some scientific advisors to step down in protest
Tag Archives: Aduhelm
-
-
Alzheimer’s Disease Drugs Aduhelm, Leqembi May Cause Brain Shrinkage: Study
Aduhelm and Leqembi side effects may actually speed up brain atrophy, making Alzheimer's disease and dementia problems worse, researchers warn.
-
Congressional Report Finds FDA Ignored Agency Protocols in Approving Biogen’s Aduhelm Alzheimer’s Drug
Biogen and FDA held numerous improperly documented meetings designed to drag Aduhelm through the approval process despite a lack of evidence showing the drug worked, the report found
-
FDA System For Approving New Drugs Found Lacking By Study
-
Lawmakers Demand FDA Documents on Aduhelm Approval
-
Distrust of FDA Drug Approval Process Leads To Hesitation Prescribing New Meds: Survey
-
Investigation Into Alzheimer’s Drug Approval Process Requested By Multiple Entities, Including FDA
-
Two FDA Advisory Committee Members Quit Over Controversial Approval of New Alzheimer’s Drug
-
Consumer Group Calls FDA Approval of New Alzheimer’s Drug “Reckless”
